TScan Therapeutics, Inc. (TCRX) Tops Q1 EPS by 54c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q1 EPS of $0.26, $0.54 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Freedom Broker Downgrades Flexsteel (FLXS) to Hold